<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kyler KE</submitter><funding>Eunice Kennedy Shriver National Institute of Child Health and Human Development</funding><funding>NICHD NIH HHS</funding><funding>National Institute of Diabetes and Digestive and Kidney Diseases</funding><funding>NIDDK NIH HHS</funding><pagination>e13782</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11022290</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(4)</volume><pubmed_abstract>In this brief report, we provide an analysis of the influence of a novel CYP2C haplotype (CYP2C:TG) on proton pump inhibitor (PPI) pharmacokinetics (PK) in children. The CYP2C:TG haplotype has been proposed to be associated with increased CYP2C19 activity. We sought to determine if this CYP2C:TG haplotype resulted in similar alterations in metabolism for proton pump inhibitors, which are primarily metabolized by CYP2C19. In a cohort of 41 children aged 6-21 participating in a PPI pharmacokinetic study, effects of the CYP2C:TG allele were assessed by fitting two linear regression models for each of the six PK outcomes assessed, the second of which accounted for the presence of the CYP2C:TG allele. The difference in R&lt;sup>2&lt;/sup> values between the two models was computed to quantify the var</pubmed_abstract><journal>Clinical and translational science</journal><pubmed_title>Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children.</pubmed_title><pmcid>PMC11022290</pmcid><funding_grant_id>K23 DK115827</funding_grant_id><funding_grant_id>T32 HD069038</funding_grant_id><pubmed_authors>Leeder JS</pubmed_authors><pubmed_authors>Staggs VS</pubmed_authors><pubmed_authors>Pearce RE</pubmed_authors><pubmed_authors>Kyler KE</pubmed_authors><pubmed_authors>Abdel-Rahman S</pubmed_authors><pubmed_authors>Gaedigk A</pubmed_authors><pubmed_authors>Toren P</pubmed_authors><pubmed_authors>Shakhnovich V</pubmed_authors></additional><is_claimable>false</is_claimable><name>Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children.</name><description>In this brief report, we provide an analysis of the influence of a novel CYP2C haplotype (CYP2C:TG) on proton pump inhibitor (PPI) pharmacokinetics (PK) in children. The CYP2C:TG haplotype has been proposed to be associated with increased CYP2C19 activity. We sought to determine if this CYP2C:TG haplotype resulted in similar alterations in metabolism for proton pump inhibitors, which are primarily metabolized by CYP2C19. In a cohort of 41 children aged 6-21 participating in a PPI pharmacokinetic study, effects of the CYP2C:TG allele were assessed by fitting two linear regression models for each of the six PK outcomes assessed, the second of which accounted for the presence of the CYP2C:TG allele. The difference in R&lt;sup>2&lt;/sup> values between the two models was computed to quantify the var</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2026-06-02T08:19:46.682Z</modification><creation>2026-05-26T03:06:48.32Z</creation></dates><accession>S-EPMC11022290</accession><cross_references><pubmed>38629502</pubmed><doi>10.1111/cts.13782</doi></cross_references></HashMap>